Research graph
References from An interpretable survival model for diffuse large B-cell lymphoma patients using a biologically informed visible neural network. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/blood-2016-01-643569
10.1182/blood-2016-01-643569 · External reference
10.1073/pnas.1205299110
10.1073/pnas.1205299110 · External reference
10.1016/j.cell.2017.09.027
10.1016/j.cell.2017.09.027 · External reference
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
10.1182/blood-2006-08-038257 · 2007 · External reference
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
10.1182/blood-2013-09-524108 · 2014 · External reference
10.1038/nm0102-68
10.1038/nm0102-68 · External reference
Development of a prognostic model for breast cancer survival in an open challenge environment
2013 · External reference
DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network
10.1186/s12874-018-0482-1 · 2018 · External reference
Integrating multi-omics data through deep learning for accurate cancer prognosis prediction
10.1016/j.compbiomed.2021.104481 · 2021 · External reference
Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling
10.1186/s12885-020-07492-y · 2020 · External reference
OSdlbcl: an online consensus survival analysis web server based on gene expression profiles of diffuse large B‐cell lymphoma
10.1002/cam4.2829 · 2020 · External reference
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma
10.1038/s41408-020-00404-0 · 2021 · External reference
10.1038/35000501
10.1038/35000501 · External reference
10.1056/nejmoa012914
10.1056/nejmoa012914 · External reference
10.1073/pnas.1732008100
10.1073/pnas.1732008100 · External reference
10.1016/j.ccell.2020.03.015
10.1016/j.ccell.2020.03.015 · External reference
10.1056/nejmoa1801445
10.1056/nejmoa1801445 · External reference
10.1038/s41591-018-0016-8
10.1038/s41591-018-0016-8 · External reference
10.1182/blood.2019003535
10.1182/blood.2019003535 · External reference
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
10.1038/s41392-023-01358-y · 2023 · External reference
Artificial intelligence and machine learning in clinical development: a translational perspective. npj Digit
2019 · External reference
10.1056/nejmra2302038
10.1056/nejmra2302038 · External reference
Using neural networks for reducing the dimensions of single-cell RNA-Seq data
2017 · External reference
Visible machine learning for biomedicine
10.1016/j.cell.2018.05.056 · 2018 · External reference
10.1038/nmeth.4627
10.1038/nmeth.4627 · External reference
10.1016/j.ccell.2020.09.014
10.1016/j.ccell.2020.09.014 · External reference
10.1038/s41586-021-03922-4
10.1038/s41586-021-03922-4 · External reference
10.1093/bioinformatics/btac636
10.1093/bioinformatics/btac636 · External reference
A Unified Approach to Interpreting Model Predictions
2017 · External reference
Machine learning–based interpretation and visualization of nonlinear interactions in prostate cancer survival
10.1200/cci.20.00002 · 2020 · External reference
Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival
10.1038/s41598-021-86327-7 · 2021 · External reference
10.1200/jco.18.01583
10.1200/jco.18.01583 · External reference
10.1158/2159-8290.cd-18-1090
10.1158/2159-8290.cd-18-1090 · External reference
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d′Etudes des Lymphomes de l′Adulte
10.1182/blood-2010-03-276246 · 2010 · External reference
10.1093/nar/gkab1028
10.1093/nar/gkab1028 · External reference
10.1093/nar/gkaa1074
10.1093/nar/gkaa1074 · External reference
10.1038/nature09671
10.1038/nature09671 · External reference
SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence
10.1182/blood.2020010432 · 2021 · External reference
Abstract 1771: characterization of RHOA inactivation as a driver of CAR-T therapy resistance in diffuse large B-cell lymphoma
10.1158/1538-7445.am2023-1771 · 2023 · External reference
Absence of BRAF and KRAS hotspot mutations in primary mediastinal and other diffuse large B-cell lymphoma
10.1182/blood.v122.21.4325.4325 · 2013 · External reference
Integrative analysis of 1001 diffuse large B cell lymphoma identifies novel oncogenic roles for Rhoa
2017 · External reference
The impact of race and ethnicity on diffuse large B-cell lymphoma (DLBCL) outcomes within the veterans health administration (VHA)
10.1182/blood-2020-142118 · 2020 · External reference
Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population
10.1080/10428194.2020.1839656 · 2021 · External reference
10.1053/j.seminhematol.2006.07.005
10.1053/j.seminhematol.2006.07.005 · External reference
10.1038/s41375-021-01285-3
10.1038/s41375-021-01285-3 · External reference
Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL
10.2147/cmar.s400013 · 2023 · External reference
